The SARS-CoV-2 Spike Protein Activates the Epidermal Growth Factor Receptor-Mediated Signaling
Vaccines · 30.03.2023 · 11 (4) · 768
DOI: 10.3390/vaccines11040768 ↗Kurz gefasst
Fachartikel in der Zeitschrift Vaccines, online erschienen am 30.03.2023. Verfasst von Abdul Rasheed Palakkott und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biology, College of Science, United Arab Emirates University, Al Ain P.O. Box 15551, United Arab Emirates. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: United Arab Emirates University, UAEU Research Office.
Abstract (Originalsprache)
The coronavirus disease-19 (COVID-19) pandemic is caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). At the molecular and cellular levels, the SARS-CoV-2 uses its envelope glycoprotein, the spike S protein, to infect the target cells in the lungs via binding with their transmembrane receptor, the angiotensin-converting enzyme 2 (ACE2). Here, we wanted to investigate if other molecular targets and pathways may be used by SARS-CoV-2. We investigated the possibility of the spike 1 S protein and its receptor-binding domain (RBD) to target the epidermal growth factor receptor (EGFR) and its downstream signaling pathway in vitro using the lung cancer cell line (A549 cells). Protein expression and phosphorylation were examined upon cell treatment with the recombinant full spike 1 S protein or RBD. We demonstrate for the first time the activation of EGFR by the Spike 1 protein associated with the phosphorylation of the canonical Extracellular signal-regulated kinase1/2 (ERK1/2) and AKT kinases and an increase in survivin expression controlling the survival pathway. Our study suggests the putative implication of EGFR and its related signaling pathways in SARS-CoV-2 infectivity and COVID-19 pathology. This may open new perspectives in the treatment of COVID-19 patients by targeting EGFR.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Biology, College of Science, United Arab Emirates University, Al Ain P.O. Box 15551, United Arab Emirates.
- Department of Basic Medical Sciences, College of Medicine, QU Health, Qatar University, Doha P.O. Box 2713, Qatar.
- Khalifa Center for Biotechnology and Genetic Engineering, United Arab Emirates University, Al Ain P.O. Box 15551, United Arab Emirates.
ORCID-Profile: Abdul Rasheed Palakkott, Khalid Muhammad, Ali Hussein Eid, Khaled M A Amiri, Mohammed Akli Ayoub, Rabah Iratni
Förderung
- United Arab Emirates University
- UAEU Research Office
Zitieren
APA
Palakkott, A. R., Alneyadi, A., Muhammad, K., Eid, A. H., Amiri, K. M. A., Akli Ayoub, M., & Iratni, R. (2023). The SARS-CoV-2 Spike Protein Activates the Epidermal Growth Factor Receptor-Mediated Signaling. Vaccines, 11(4), 768. https://doi.org/10.3390/vaccines11040768
Vancouver
Palakkott AR, Alneyadi A, Muhammad K, Eid AH, Amiri KMA, Akli Ayoub M, et al. The SARS-CoV-2 Spike Protein Activates the Epidermal Growth Factor Receptor-Mediated Signaling. Vaccines. 2023;11(4):768. doi:10.3390/vaccines11040768
BibTeX
@article{Palakkott2023,
author = {Palakkott, Abdul Rasheed and Alneyadi, Aysha and Muhammad, Khalid and Eid, Ali Hussein and Amiri, Khaled M A and Akli Ayoub, Mohammed and Iratni, Rabah},
title = {The SARS-CoV-2 Spike Protein Activates the Epidermal Growth Factor Receptor-Mediated Signaling},
journal = {Vaccines},
year = {2023},
volume = {11},
number = {4},
pages = {768},
doi = {10.3390/vaccines11040768}
}
EUVIMED